Q-omics provides the consensus-scored TAF1 profile across patient tissues and cancer cell-line models. TAF1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TAF1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TAF1 RNA expression shows 21,394 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, COAD, and UVM as cancer lineages where TAF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1 survival associations across molecular data types. TAF1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1 RNA expression–survival associations across cancer types. High TAF1 expression shows unfavorable associations in COAD, MESO and KIRP, but favorable associations in SCLC, KIRC and BLCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TAF1 RNA expression.
This table summarizes TAF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TAF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LIHC, CHOL and READ. The COAD box plot shows higher TAF1 RNA expression in tumor versus normal tissue (log2 FC = +0.483, t-test p < 0.001).
This table shows molecular features associated with TAF1 in patient tissues and cancer cell lines. In patient samples, TAF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
